Loeffler Anette, Herrick Desiree, Allen Serena, Littlewood Janet D
Department of Clinical Science and Services, Royal Veterinary College, North Mymms, Hertfordshire, AL9 7TA, UK.
Veterinary Dermatology Referrals, Landbeach, Cambridge, UK.
Vet Dermatol. 2018 Dec;29(6):526-e176. doi: 10.1111/vde.12685. Epub 2018 Sep 3.
Allergic pruritus and urticaria in the horse are challenging for veterinarians and owners; little is known about their long-term management.
To summarize intradermal allergen test results (IDT), and to assess owners' perceptions of skin disease and the effects of medical treatment and management changes in their atopic horses over time.
Eighty two horses with atopic dermatitis in southeastern England between 2006 and 2011.
The IDT results were reviewed retrospectively. Owners completed telephone questionnaires on skin changes, medication, effect of allergen-specific immunotherapy (ASIT) and management.
Sixty one owners (74.4%) could be contacted, an average of 5.9 years (range 28-88 months) after IDT; of those, three could not be enrolled. Of the 58 remaining horses, eleven (19%) were deceased at the time of owner interview, including four (6.9%) euthanized due to uncontrollable skin disease. The remaining 47 owners reported that the signs of skin disease had not been seen for at least two years in 18 horses (38.3%), including two that only flared with known triggers. Twenty nine horses (61.7%) still required medication to control skin disease although 25 (53.2%) required less since testing. Owners reported benefit from ASIT in nine of 14 horses (64.3%) from glucocorticoids in 33 of 35 (94.3%) and from antihistamines in 17 of 28 (60.7%). Specific management changes were implemented for 22 horses and reported as beneficial in nine of 22 (40.9%).
Equine atopic dermatitis may not always be chronic, but severe cases appear difficult to control. IDT may help to formulate ASIT and can help to guide management changes.
马匹的过敏性瘙痒和荨麻疹给兽医和马主带来了挑战；人们对其长期管理知之甚少。
总结皮内过敏原试验结果（IDT），并评估马主对皮肤疾病的看法以及随着时间推移其特应性马匹的药物治疗和管理变化的效果。
2006年至2011年期间英格兰东南部的82匹患有特应性皮炎的马。
对IDT结果进行回顾性分析。马主完成了关于皮肤变化、用药、过敏原特异性免疫疗法（ASIT）的效果和管理的电话问卷调查。
61位马主（74.4%）能够被联系上，平均在IDT后5.9年（范围28 - 88个月）；其中，3位无法纳入研究。在其余58匹马中，11匹（19%）在马主接受访谈时已经死亡，包括4匹（6.9%）因无法控制的皮肤疾病而实施安乐死。其余47位马主报告称，18匹马（38.3%）至少两年没有出现皮肤疾病症状，其中2匹仅在已知触发因素时发作。29匹马（61.7%）仍需要药物来控制皮肤疾病，尽管25匹（53.2%）自检测后所需药物减少。马主报告称，14匹马中有9匹（64.3%）从ASIT中获益，35匹马中有33匹（94.3%）从糖皮质激素中获益，28匹马中有17匹（60.7%）从抗组胺药中获益。对22匹马实施了特定的管理变化，22匹中有9匹（40.9%）报告称有益。
马的特应性皮炎不一定总是慢性的，但严重病例似乎难以控制。IDT可能有助于制定ASIT，并有助于指导管理变化。
